drugset / Trial / NCT05751759
Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of mitiperstat.
Timeline
- Start
- 2023-03-20
- Primary completion
- 2024-11-21
- Completion
- 2024-11-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitiperstat | Small molecule | — | Oral |
Indications
No indication recorded.